-transparent.png){kind=logo}
The increase in life-span (ILS) of tumor-bearing mice caused by recombinant interleukin-2 (RIL-2) was studied in the solid tumor adenocarcinoma 755 system. With long-term treatment (Days 5-12), RIL-2 (10(5) U/mouse) showed a weak effect (24% ILS), but short-term RIL-2 treatment (Days 5-8 or 9-12) had hardly any effect. Mitomycin, at 2 mg/kg (maximum nontoxic dose), caused 35% ILS with Days 5-8 treatment and only 12% ILS with Days 9-12 treatment. Sequential treatment with mitomycin (Days 5-8) and RIL-2 (Days 9-12) markedly enhanced antitumor activity (88% ILS). This value is significantly greater than that of mitomycin alone or RIL-2 alone (P less than 0.01). Furthermore, mitomycin followed by RIL-2 markedly augmented killing activity of spleen cells that are cytotoxic in vitro. These results indicate that RIL-2 markedly affects the inhibition of growth of a tumor treated with an antitumor agent.
M Ligo, and
M Sakurai, and
N Saijo, and
A Hoshi
August 1990,
Journal of biological response modifiers,
M Ligo, and
M Sakurai, and
N Saijo, and
A Hoshi
May 1990,
The Japanese journal of surgery,
M Ligo, and
M Sakurai, and
N Saijo, and
A Hoshi
April 1989,
Journal of biological response modifiers,
M Ligo, and
M Sakurai, and
N Saijo, and
A Hoshi
October 1978,
Meditsinskaia radiologiia,
M Ligo, and
M Sakurai, and
N Saijo, and
A Hoshi
August 1958,
Cancer research,
M Ligo, and
M Sakurai, and
N Saijo, and
A Hoshi
May 1991,
Blood,
M Ligo, and
M Sakurai, and
N Saijo, and
A Hoshi
January 1991,
Biotherapy (Dordrecht, Netherlands),
M Ligo, and
M Sakurai, and
N Saijo, and
A Hoshi
January 1992,
Urological research,
M Ligo, and
M Sakurai, and
N Saijo, and
A Hoshi
July 2007,
Biochimica et biophysica acta,
M Ligo, and
M Sakurai, and
N Saijo, and
A Hoshi
April 2004,
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie,
